PRMA Insights: The Roadmap to Pricing and Reimbursement Success
Each publication delivers
Each comprehensive disease-specific publication provides a detailed review of the following issues in the pricing and reimbursement in the major markets:
-
The key pricing and reimbursement issues and treatments by country and the implications for products seeking nominations for the disease area is now critical to commercial success.
-
How payers have critically evaluated the data packages for existing products.
-
An in-depth critical review of the pricing and reimbursement and HTA assessments in each disease area in the major markets.
-
The price existing products have achieved and their reimbursement status in each country.
-
The value propositions and arguments manufacturers have submitted for their products.
-
A review of the relevant risk sharing agreements for products indicated for each disease.
-
An overview of the disease area with a focus on the key issues shaping the market access landscape.
-
The implications surrounding the choice of comparators and endpoints included in the clinical trials in pricing and reimbursement.
-
A comprehensive review of the products, regulatory nominations, key supporting data packages and the position in clinical guidelines.
-
The key learnings and market access insights for developing a new product in the relevant disease area.
-
How payers view combination and maintenance therapy.
-
A review of the epidemiology and burden of the relevant disease with insights into evidence gaps and the impact on your health outcomes strategy.
-
A review of the existing instruments used to measure Health Related Quality of Life (HRQoL) in the relevant disease, opportunities for the inclusion of HRQoL data in your label and how this could differentiate your product and impact pricing and reimbursement.
To find out more or register your disease area interest, click here
Fill in the fields below and press submit. A member of our team
will respond
shortly.
